pcgmolecular is a preventive care diagnostic company driven to change national figures concerning disease and survival rates. As a proven pioneer in the industry, PCG Molecular is dedicated to the research and development of genetic, molecular screens that detect problems early, are easy to administer, and bring pliable business models to practitioners that incentivize change. Our company offers physicians, hospitals, and patients more than twenty years of pathology experience with highly-trained, Board Certified pathologists and molecular biologists that understand the unique clinical and business needs within hospital and outpatient settings.
Armando Moncada, MD, FCAP
CEO & Founder
Dr. Armando Moncada is the CEO and founder at PCG Molecular. He is committed to seeking new methods to make preventive health care easier for both patients and practitioners while reducing the overall cost of health care. With more than 20 years of experience in pathology practice and research, Dr. Moncada has special expertise in oncologic pathology and molecular microbiology.
Dr. Moncada has fulfilled several roles throughout his career. He is a seasoned CAP inspector who has served as the state commissioner for the College of American Pathologists.
After having attended Tulane University School of Medicine in New Orleans where he completed his training in anatomic and clinical pathology, he completed a surgical pathology fellowship at The City of Hope National Medical Center in Duarte, California. Following the completion of his fellowship, Dr. Moncada was selected to serve as assistant professor of pathology at Baylor College of Medicine in Houston, Texas.
Dr. Moncada has lectured extensively on the subjects of cancer and infectious disease prevention.